Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target hoisted by equities researchers at UBS Group from $162.00 to $176.00 in a research note issued to investors on ...
Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Neurocrine Biosciences in ...
Investor's Business Daily on MSN11h
Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And AlphabetThe week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback